君实生物(01877.HK)民得维治疗轻中度COVID-19获常规批准

阿斯达克财经
Jan 12, 2025

君实生物(01877.HK) 公布,控股子公司上海旺实收到中国国家药品监督管理局核准签发通知书,氢溴酸氘瑞米德韦片(商品名:民得维)用于治疗轻中度新型冠状病毒感染“COVID-19”的成年患者的适应症获得国家药监局同意,由附条件批准转为常规批准。民得维是一款口服核苷类抗病毒药物,可抑制SARS-CoV-2复制。本次常规批准基于多项临床及非临床研究,结果显示,在轻、中度COVID-19患者中,民得维...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10